Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-10
Mock James M Files Moderna (MRNA) Form 4 - September 10, 2026
Mock James M traded 54.7K MRNA shares worth $5.3M in this Form 4 filing, reported to the SEC on 2026-09-10.
- Insider
- Mock James M
- Issuer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Period
- 2026-09-10
- Accession
- 0001682852-26-000174
- Source
- Official filing on sec.gov ↗
Transactions (4)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Mock James M | 2026-09-10 | Buy | 19.8K | $30.96 | $614.1K | Direct |
| Mock James M | 2026-09-10 | Sell | 19.8K | $134.49 | $2.7M | Direct |
| Mock James M | 2026-09-10 | Sell | 15.0K | $134.49 | $2.0M | Direct |
| Net change | −15.0K | −$4.1M | ||||
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
Track MRNA insider activity
Get alerted when Moderna Inc. executives buy or sell their shares.